A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

NCT06236880 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: GM-2505

Sponsor

Gilgamesh Pharmaceuticals